Valuebase
AI NativeLeveraging AI and data science to drive access to medicines
Est 2022
Published Sep 19, 2026
No authoritative market share data was found in accessible sources. Vendor-reported adoption figures are not independently verified.
| Starting Price | Published pricing not available; vendor quote required and varies by jurisdiction | Published pricing not available; vendor quote required | Published pricing not available; vendor quote required |
| Best for | Jurisdictions seeking auditable automated valuation models and data QA/enrichment while retaining existing CAMA systems | Large jurisdictions pursuing an enterprise AI appraisal deployment with deeper operational integration | Jurisdictions needing a full system of record for appraisal and assessment administration |
| Key Strength | Rapid deployment for data-focused pilots and assessor utilities for targeted tasks | Enterprise workflow coverage and claims of deeper integration with source systems | Mature CAMA feature breadth and integrated appraisal workflows |
| Key Weakness | Limited publicly available security/compliance documentation and limited third-party review coverage; integration depth was questioned in some municipal comparisons | Typically involves heavier enterprise procurement and implementation effort; vendor-published metrics require independent validation | Not AI-first; modernization may require additional vendors or modules |
—
Valuebase versus C3 AI:
Valuebase versus Tyler/Aumentum ecosystems:
Buyer decision pattern: